MYGN $25.67

0.16 (0.6%)

MYGN Profile

Health Care
2 Billion
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease or tailor treatment for already diagnosed patients. The firm produces myRisk, a 28-gene panel with the capability to identify the elevated risk of developing eight types of cancer. Other diagnostic products include BRACAnalysis CDx, GeneSight, Vectra DA, and Prolaris. The firm also offers biomarker discovery and companion diagnostic services to pharmaceutical and biotechnology companies.

MYGN Earnings

Earnings Per Share (EPS)
Price To Earnings Ratio (P/E)
2nd Quarter Earnings Report
for Apr, May & Jun

Tue, Aug 13, 2019 (115 days ago)
Since Earnings Report -43.3%
3rd Quarter Earnings Report
for Jul, Aug & Sep

Mon, Nov 4, 2019 (32 days ago)
Since Earnings Report -24.1%

MYGN Dividend

Ex-Dividend Date
Dividend Pay Date
Dividend Payments

MYGN Charts

All Time High $69.00 Mon, Nov 6, 2000

Symbol Price Day YTD
MYGN $25.67 -0.6% -11.5%

Linde, Avery Dennison Corp, Mosaic Co, Sociedad Quimica y Minera S.A. Common Stock & Kronos Worldwide Inc.

Apollo Global Management LLC, WPP plc American Depositary Shares & Medical Properties Trust Inc.

Symbol Surfing

How can we make Symbol Surfing better?


©2019 Symbol Surfing All Rights Reserved.

Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.

Cookies Policy Terms Of Service Privacy Policy